Becton, Dickinson and Company (BD) has announced a collaboration with CerTest Biotec for the development of a molecular diagnostic test for the monkeypox virus.

As part of the partnership, the companies will develop the VIASURE Monkeypox CE/IVD molecular test using the BD MAX molecular diagnostic open system reagent suite.

The reagent suite will also be used to validate the diagnostic test on the BD MAX System, which is a fully integrated, automated platform for nucleic acid extraction and real-time PCR.

The BD MAX System provides results for up to 24 samples, within three hours, across multiple conditions.

Available for BD MAX System users, the new RT-PCR detection kit is expected to help understand the global spread of the disease, said BD.

The company noted that the Monkeypox PCR Detection Kit for the BD MAX System will be provided in a lyophilized format similar to other CerTest tests.

The diagnostic kit comes in a tube that fits into the test-specific position on the BD MAX ExK TNA extraction strip that is provided by BD.

BD Molecular Diagnostics vice-president Nikos Pavlidis said: “Enabling labs to rapidly respond to unexpected challenges is the kind of evolving health care situations for which the BD MAX open system reagent suite is designed.

“Through our collaboration with CerTest and their ability to rapidly transfer assays on the BD MAX System, we will enable BD MAX System users around the world to access a test for the confirmation of monkeypox.”

The company offers a range of tests on the BD MAX System that cover sexually transmitted infections, respiratory infections, gastrointestinal infections, women’s health diagnostics and healthcare-associated infections.

For the system, BD provides a suite of open system reagents that allow labs to completely automate and streamline their Lab Developed Tests and develop complementary assays on the system in partnership with customers.